Trial reportObesity (Silver Spring, Md.)2026
One Year of Exercise After Weight Loss Increases Postprandial GLP-1 Secretion in Contrast to Usual Activity or GLP-1 Receptor Agonist Treatment.
Trial report in Obesity (Silver Spring, Md.), 2026. The graph read 1 number from its abstract, feeding 1 cell of the map, but it casts no vote: it is a later paper about NCT04122716, whose primary report (PMID 33951361) speaks for the trial. It reports registered trial NCT04122716. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
Read, but not usablea number the graph found but could not read as for or against
RESULTS: Diet-induced weight loss did not change late-phase GLP-1 response (3%; 95% CI, -4%-10%).
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
Diet, exercise & lifestyle×body weight & composition
No readable resultOpen on the map →What to test next →3 readable studies in this cell: 2 favour the treatment, 0 find no difference, 1 favour the comparator.
This paper's own estimate is on a different scale from the rest of the cell, so it is not drawn here.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Synergy Effect of the Appetite Hormone GLP-1 (LiragluTide) and Exercise on Maintenance of Weight Loss and Health After a Low Calorie Diet - the S-LiTE Randomized Trial
Who cites it
8 citing papers in PubMed.
- One Year of Exercise After Weight Loss Increases Postprandial GLP-1 Secretion in Contrast to Usual Activity or GLP-1 Receptor Agonist Treatment.Obesity (Silver Spring, Md.) · 2026Trial
- Comparative Efficacy of GLP-1 Receptor Agonists, Exercise, and Their Combination on Body Composition and Glucolipid Metabolism in Adults With Overweight or Obesity: A Network Meta-Analysis of Randomized Controlled Trials.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Review
- Changes in GLP-1 and GIP During Endurance Training in Competitive Triathletes: A Pilot Observational Study.Journal of clinical medicine · 2026Article
- Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series.Obesity (Silver Spring, Md.) · 2026Article
- Seeing Beyond GLP-1: A Systems View of Sustainable Obesity Care.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2026Review
- Review
- Physical activity promotes gut adaptation, nutrient responsiveness, and sensitivity to gut peptides in male mice.EBioMedicine · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The marked sentences are the ones the graph read a number from.
objectiveIncretin-based obesity medication maintains weight loss by mimicking the appetite-inhibiting hormone GLP-1. Interestingly, chronic exercise may improve postprandial appetite control by increasing late postprandial secretion of endogenous GLP-1. Therefore, we investigated whether an exercise program after weight loss could increase late-phase postprandial GLP-1 secretion.
methodsThis study is an exploratory analysis of adults with obesity (n = 195) who lost 13.1 kg on a low-calorie diet and were randomized to 52 weeks of either usual activity, moderate-to-vigorous intensity exercise, the GLP-1 receptor agonist liraglutide (3.0 mg/day), or the combination. The primary endpoint was change in late-phase GLP-1 response to a 3-h liquid mixed meal test before and after diet-induced weight loss and after 1 year of intervention.
resultsDiet-induced weight loss did not change late-phase GLP-1 response (3%; 95% CI, -4%-10%). One year of exercise increased late-phase postprandial GLP-1 response within the group by 37% (95% CI, 20%-57%), and this increase was 25% greater (95% CI, 3%-51%, p = 0.02) compared to the usual activity group. Late-phase postprandial GLP-1 response was unchanged in both groups treated with GLP-1 receptor agonist compared to placebo.
conclusionsOne year of exercise increased late-phase postprandial GLP-1 response, which may prevent increased appetite after weight loss and thereby weight regain.
trial registrationEudraCT number: 2015-005585-32; ClinicalTrials.gov identifier: NCT04122716.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.